Precipio Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Precipio's stock with a target price of $19, indicating strong growth potential.
Financial Health
Precipio Inc shows modest revenue and cash flow, but its profitability is somewhat limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRPO
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Niche diagnostic focus
Precipio targets oncology and haematology diagnostics, a specialised area where clinical adoption can drive growth — though adoption and reimbursement can be uncertain.
Small‑cap volatility
With a market cap around $35M, PRPO can be highly volatile and illiquid; price swings may be large and outcomes binary around milestones.
Regulation and partnerships
Regulatory approvals and strategic partnerships can materially affect prospects, so investors often monitor clinical, regulatory and commercial updates closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
